List of works - Clas Malmeström

A Sensitive Method for Detecting Peptide-specific CD4+ T Cell Responses in Peripheral Blood from Patients with Myasthenia Gravis

scientific article published on 24 October 2017

A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.

scientific article published in January 2002

Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.

scientific article

An observational study of alemtuzumab following fingolimod for multiple sclerosis.

scientific article published on 10 January 2017

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

scientific article

CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment

scientific article published on 13 February 2014

Cerebrospinal fluid CD4+/CD8+ ratio in diagnosing neurosarcoidosis

scientific article published on 13 June 2020

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis

scientific article published on 27 October 2016

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.

scientific article

Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis

scientific article published on 15 October 2012

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis

scientific article published on 21 November 2019

Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies

scientific article published in March 2017

Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis

scientific article published on 29 January 2016

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

scientific article

Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials

scientific article published in January 2012

First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS

scientific article published on 01 August 2014

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

scientific article published in January 2011

High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis

scientific article published on 09 March 2017

IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles

scientific article published on 19 April 2006

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

scientific article published on 23 May 2013

Inflammation-related plasma and CSF biomarkers for multiple sclerosis

scientific article published on 26 May 2020

Intrathecal immunoreactivity in people with or without previous infectious mononucleosis

scientific article published on 16 May 2020

MS risk genes are transcriptionally regulated in CSF leukocytes at relapse

scientific article published on 20 August 2012

MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS).

scientific article

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

scientific article published on 27 October 2017

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

scientific article published on 13 June 2013

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS

scientific article published on 01 December 2003

Neuromyelitis optica--important differential diagnosis to MS. Early treatment initiation crucial for the prognosis

scientific article published on December 2010

Processing in prefrontal cortex underlies tactile direction discrimination: An fMRI study of a patient with a traumatic spinal cord lesion.

scientific article

Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis

scientific article published on 19 January 2009

Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.

scientific article published on 29 August 2015

Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF

scientific article

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy

scientific article

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

scientific article published on 31 March 2016

Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.

scientific article

Serum levels of LIGHT in MS

article by Clas Malmeström et al published 4 October 2012 in Multiple Sclerosis Journal

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

scientific article published in August 2011

Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone

The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis

scientific article

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

scientific article published on November 2012

Upper Respiratory Infections and MRI Activity in Relapsing-Remitting Multiple Sclerosis

scientific article published on 29 August 2015

YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis

scientific article published on 22 January 2016

List of works by Clas Malmeström

A Sensitive Method for Detecting Peptide-specific CD4+ T Cell Responses in Peripheral Blood from Patients with Myasthenia Gravis

A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.

Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.

An observational study of alemtuzumab following fingolimod for multiple sclerosis.

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment

Cerebrospinal fluid CD4+/CD8+ ratio in diagnosing neurosarcoidosis

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.

Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis

Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies

Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials

First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis

IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

Inflammation-related plasma and CSF biomarkers for multiple sclerosis

Intrathecal immunoreactivity in people with or without previous infectious mononucleosis

MS risk genes are transcriptionally regulated in CSF leukocytes at relapse

MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS).

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS

Neuromyelitis optica--important differential diagnosis to MS. Early treatment initiation crucial for the prognosis

Processing in prefrontal cortex underlies tactile direction discrimination: An fMRI study of a patient with a traumatic spinal cord lesion.

Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis

Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.

Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.

Serum levels of LIGHT in MS

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone

Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone

The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Upper Respiratory Infections and MRI Activity in Relapsing-Remitting Multiple Sclerosis

YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis